Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at University of Chicago Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 2:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1115
Shown on this page
12
Current sort
Recently updated
Campus scope
University of Chicago Medicine, Chicago, IL
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within University of Chicago Medicine, Chicago, IL. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1009–1020 of 1,115 matching trials with a site at University of Chicago Medicine, Chicago, IL.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Not applicable Interventional

Guideline-directed Management and Therapy (GDMT) for the Prevention of Postpartum Cardiac Dysfunction in Preeclamptic African American Women

NCT05534932
Site status not listed — check the official record
View directory record Official record
Conditions
Preeclampsia Postpartum
Interventions
Remote Patient Monitoring
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Nov 9, 2026, 2:24 PM EST
Recruiting Phase 4 Interventional Accepts healthy volunteers

A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection

NCT06008860
Status at this site: Recruiting
View directory record Official record
Conditions
COVID-19
Interventions
Experimental: Primary Cohort, Placebo Comparator: Primary Cohort - Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Nov 9, 2026, 2:24 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Mirai-MRI: Validation of AI Models for Breast Cancer Risk

NCT07121972
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Cancer Risk, Breast Cancer Risk
Interventions
Magnetic resonance imaging (MRI), Artificial Intelligence (AI)
Procedure · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 89 Years · Female only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
4
States / cities
San Diego, California • San Francisco, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Nov 9, 2026, 2:24 PM EST
Active, not recruiting Phase 2 Interventional

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

NCT03539536
Site status not listed — check the official record
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Telisotuzumab vedotin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
56
States / cities
Mobile, Alabama • Phoenix, Arizona • Springdale, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Nov 9, 2026, 2:24 PM EST
Recruiting Phase 3 Interventional

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

NCT05929768
Status at this site: Recruiting
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Paclitaxel, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
955
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 654 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Nov 9, 2026, 2:24 PM EST
Recruiting Phase 1 Interventional

The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial

NCT06871111
Status at this site: Recruiting
View directory record Official record
Conditions
Liver Diseases, Liver Failure, Cirrhosis, Liver
Interventions
Commensal Bacteria Strains
Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Nov 9, 2026, 2:24 PM EST
Recruiting Phase 1 Interventional

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

NCT03595917
Status at this site: Recruiting
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
Interventions
ABL001, Dasatinib, Prednisone, Blinatumomab
Drug
Lead sponsor
Marlise Luskin, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Nov 9, 2026, 2:24 PM EST
Active, not recruiting Phase 4 Interventional

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

NCT03229200
Site status not listed — check the official record
View directory record Official record
Conditions
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease, Solid Tumor
Interventions
Ibrutinib
Drug
Lead sponsor
Pharmacyclics Switzerland GmbH
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
34
States / cities
Burbank, California • Duarte, California • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Nov 9, 2026, 2:24 PM EST
Recruiting Phase 3 Interventional

Stress Hydrocortisone In Pediatric Septic Shock

NCT03401398
Status at this site: Recruiting
View directory record Official record
Conditions
Septic Shock
Interventions
Hydrocortisone, sodium succinate, Normal saline
Drug
Lead sponsor
Jerry Zimmerman
Other
Eligibility
1 Month to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
18
States / cities
Tucson, Arizona • Los Angeles, California • Oakland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Nov 9, 2026, 2:24 PM EST
Recruiting No phase listed Observational

US National OCS Heart Perfusion (OHP) Registry

NCT05915299
Status at this site: Recruiting
View directory record Official record
Conditions
Heart Transplant
Interventions
OCS Heart
Device
Lead sponsor
TransMedics
Industry
Eligibility
Not listed
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
37
States / cities
Phoenix, Arizona • La Jolla, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Nov 9, 2026, 2:24 PM EST
Recruiting Phase 3 Interventional

Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

NCT05918211
Status at this site: Recruiting
View directory record Official record
Conditions
Single Ventricle Heart Disease
Interventions
Udenafil, Placebo
Drug
Lead sponsor
Mezzion Pharma Co. Ltd
Industry
Eligibility
12 Years to 18 Years
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
37
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Nov 9, 2026, 2:24 PM EST
Active, not recruiting Phase 2 Interventional Results available

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

NCT04385277
Site status not listed — check the official record
View directory record Official record
Conditions
Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, FDG-Positron Emission Tomography, Iobenguane I-123, Irinotecan, Isotretinoin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sargramostim, Temozolomide
Procedure · Biological · Radiation + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
70
States / cities
Mesa, Arizona • Little Rock, Arkansas • Downey, California + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Nov 9, 2026, 2:24 PM EST

About this University of Chicago Medicine institution page

What this page lists
ClinicalTrials.gov records that list University of Chicago Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.